Doximity, Inc. (DOCS): Price and Financial Metrics
GET POWR RATINGS... FREE!
DOCS Stock Price Chart Interactive Chart >
DOCS Price/Volume Stats
|Current price||$34.44||52-week high||$107.79|
|Prev. close||$33.92||52-week low||$27.06|
|Day high||$34.84||Avg. volume||2,381,355|
|50-day MA||$42.99||Dividend yield||N/A|
|200-day MA||$59.63||Market Cap||6.59B|
Doximity, Inc. (DOCS) Company Bio
Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's cloud-based platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical companies and health systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Most Popular Stories View All
DOCS Latest News Stream
|Loading, please wait...|
DOCS Latest Social Stream
View Full DOCS Social Stream
Latest DOCS News From Around the Web
Below are the latest news stories about Doximity Inc that investors may wish to consider to help them evaluate DOCS as an investment opportunity.
Healthcare is the smart play in this bear market. Here''s why these three Fool.com contributors like Doximity, Amgen, and Novocure.
These two companies are unsung heroes in their markets, and that could mean they are undervalued today.
Robert W. Baird analyst Vikram Kesavabhotla maintained a Buy rating on Doximity (DOCS – Research Report) on February 13 and set a price target of $68.00. The company's shares closed last Wednesday at $56.97. According to TipRanks.com, Kesavabhotla 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -12.7% and a 38.3% success rate. Kesavabhotla covers the Technology sector, focusing on stocks such as Tabula Rasa HealthCare, InnovAge Holding, and GoodRx Holdings. Currently, the analyst consensus on Doximity is a Moderate Buy with an average price target of $69.00, implying a 22.2% upside from current levels.
Doximity's New Report Finds Adoption of Telemedicine Growing, Majority of Patients Plan for Virtual Care Post-Pandemic
Over 73% of patients plan to continue using telemedicine platforms post-pandemic, according to Doximity's second edition of its State of Telemedicine Report, which was released today. As part of the report, Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, analyzed adoption of telemedicine across its physician user base from January 2020 through June 2021 and conducted a study of patients' experiences with telemedicine during the same time frame.
Monday’s Top Analyst Upgrades and Downgrades: Chewy, Coca-Cola, GlaxoSmithKline, Micron Technology, SoFi, Teladoc, Twitter, Walmart and More
Monday''s top analyst upgrades and downgrades included Chewy, Cloudflare, Coca-Cola, Doximity, Ideanomics, GlaxoSmithKline, Micron Technology, SoFi Technologies, Teladoc Health, Twitter and Walmart.
DOCS Price Returns